In this study, we first confirmed that SGLT2 inhibitors indeed carry a risk of bladder cancer, and even bile duct cancer, with this risk being primarily concentrated in dapagliflozin and empagliflozin. The gene discussed is SLC5A2; the disease is urinary bladder carcinoma.